Last week, our CTO Robert Berke took the stage at the AI+X Summit in Zurich, presenting on ‘Multimodal Foundation Models in Oncology: From Research to Clinical Impact.’ It was inspiring to see so much interest in the transformative potential of foundation models in oncology care. We are also happy about the valuable feedback and insights we received from the attendees, helping us with future product development.
kaiko.ai’s Post
More Relevant Posts
-
“How would you describe the TROP2 Quantitative Continuous Scoring Lung Trial?” Dr. Paul Bunn shares his thoughts following #WorldLung Don't miss out on the latest developments in oncology! Let us show you how we can get the insights you need; from the HCPs you want to hear from - even during busy congress season! #WCLC #LungCancerTrials #LungCancerData #OnvivExpertNetwork
-
Cancer EXPERT Now provides a benefit like nothing else. Members have access to the top Oncology influencers to inform on their case in an unbiased, agnostic manner. The peace of mind members need when facing the scariest news they’ve ever faced. To know you have choices, and you’ve heard it from the Top Expert in your cancer is empowering, and simply priceless. Our Experts are those all others look to for guidance. #benefits #healthinsurance #virtualcare #cancer
Post-SMR Congress, we asked Dr. Vernon Sondak what the Castle Biosciences Decision DX melanoma test could mean for patient testing. Here’s what he had to say. Don't miss out on the latest developments in oncology! Let us show you how we can get the insights you need from the experts you want to hear from. #OnvivExpertNetwork #SMR2024 #CongressInsights #Melanoma
-
📖 Prof. Jan Vermorken, Editor-in-Chief of #AnnalsOfOncology from 2009 to 2014, reflects on the journal’s evolution and its role in advancing oncology to mark its 35th anniversary. He discusses key milestones, including the growth of ESMO, the journal's multidisciplinary approach, and its global influence on oncology research. 🔗 Read the full interview: https://ow.ly/Gcvx50UbMu0
-
-
See how #Medidata and #EORTC are working together to enhance the oncology trial patient experience and unlock unparalleled access to clinical data. #ESMO24 #LifeSciences #Medidata
We’re thrilled to build on our collaboration with EORTC - European Organisation for Research and Treatment of Cancer! 🤝 Together, we will enhance the oncology trial patient experience and unlock unparalleled access to clinical data—all powered by the Medidata platform. Find us this week at the ESMO - European Society for Medical Oncology Congress to learn more: https://mdso.io/706 #ESMO24 #LifeSciences #Medidata
-
-
Post-SMR Congress, we asked Dr. Vernon Sondak what the Castle Biosciences Decision DX melanoma test could mean for patient testing. Here’s what he had to say. Don't miss out on the latest developments in oncology! Let us show you how we can get the insights you need from the experts you want to hear from. #OnvivExpertNetwork #SMR2024 #CongressInsights #Melanoma
-
Driving exponential business growth through innovative solutions and dynamic client relationships
From the benefits and challenges of Project Optimus to practical strategies to implementing its guidance, Matt Cooper's and Jim Eamma's article shares critical insights into the future of oncology studies. Learn more today: https://bit.ly/3XOS5bO
-
-
Catch up on critical advances in precision oncology from 2024! Our Best of Precision Oncology Conference content provides all the updates you need in one place. 🎯 Discover insights across key tumor sites, patient-centered therapies, and the latest in diagnostics—available anytime, anywhere. Learn from top experts and gain practical tools to elevate your practice. Watch now: https://ow.ly/NEca50Ug2IV #BOPO24 #PrecisionOncology
-
-
From the benefits and challenges of Project Optimus to practical strategies to implementing its guidance, Matt Cooper's and Jim Eamma's article shares critical insights into the future of oncology studies. Learn more today: https://bit.ly/3ZPNmcu
-
-
From the benefits and challenges of Project Optimus to practical strategies to implementing its guidance, Matt Cooper's and Jim Eamma's article shares critical insights into the future of oncology studies. Learn more today: https://bit.ly/3Yo675S
-
-
From the benefits and challenges of Project Optimus to practical strategies to implementing its guidance, Matt Cooper's and Jim Eamma's article shares critical insights into the future of oncology studies. Learn more today: https://bit.ly/3A44Asg
-
